Related Experiment Video

Updated: Jul 15, 2026

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
10:02

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Published on: March 12, 2020

Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder

Sharon B Wigal1, Suneel Gupta, Laurence Greenhill

  • 1Child Development Center,University of California, Irvine, California 92612, USA. sbwigal@uci.edu

Journal of Child and Adolescent Psychopharmacology
|May 11, 2007
PubMed

Insights

Preschool children with ADHD showed higher exposure to methylphenidate (MPH) due to slower metabolism and absorption compared to school-aged children. This highlights age-related differences in MPH pharmacokinetics for effective treatment strategies.

Area of Science:

  • Pharmacology
  • Pediatrics
  • Neuroscience

Background:

  • Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children.
  • Methylphenidate (MPH) is a widely prescribed stimulant medication for ADHD treatment.
  • Understanding age-specific pharmacokinetics (PK) is crucial for optimizing MPH dosing in pediatric populations.

Purpose of the Study:

  • To compare the pharmacokinetics of immediate-release methylphenidate (MPH) in preschool-aged children (4-5 years) and school-aged children (6-8 years) diagnosed with ADHD.
  • To investigate how age influences MPH absorption, metabolism, and overall exposure in young children with ADHD.

Main Methods:

  • A cohort of preschool (n=14) and school-aged (n=9) children with ADHD received titrated doses of immediate-release MPH.
  • Blood samples were collected predose and at 1, 2, 4, and 6 hours post-administration to measure MPH concentrations.
  • Nonlinear modeling was used to determine key pharmacokinetic parameters: C(max), t(1/2), and CL.

Main Results:

  • No significant differences were observed in the mean mg dose or weight-adjusted mg/kg dose of MPH between the two age groups.
  • Preschool children exhibited significantly higher dose-normalized peak plasma concentrations (C(max)) compared to school-aged children (p=0.003).
  • Clearance (CL) of MPH was significantly slower in preschool children than in school-aged children (p=0.0002).

Conclusions:

  • Age significantly impacts the absorption and metabolism of MPH in children with ADHD.
  • Preschool children demonstrate greater MPH exposure than school-aged children when administered the same weight-adjusted dose.
  • These findings underscore the need for further research into age-related PK differences to guide MPH dosing strategies in pediatric ADHD treatment.
Abstract

More Related Videos

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

Using Brain Activation (nir-HEG/Q-EEG) and Execution Measures (CPTs) in a ADHD Assessment Protocol13:09

Using Brain Activation (nir-HEG/Q-EEG) and Execution Measures (CPTs) in a ADHD Assessment Protocol

Published on: April 1, 2018

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...